{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:28:34Z","timestamp":1794454114042,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.arcmed.2023.102917","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:47:55Z","timestamp":1700675275000},"page":"102917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacological Treatment of Non-Functioning Pituitary Adenomas"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-2209","authenticated-orcid":false,"given":"Guadalupe","family":"Vargas-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldomero","family":"Gonzalez-Virla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alfonso","family":"Romero-Gameros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102917_bib0001","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0002","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3171\/jns.2006.104.6.884","article-title":"Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination","volume":"104","author":"Arita","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102917_bib0003","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/eje.0.1490123","article-title":"A survey of pituitary incidentaloma in Japan","volume":"149","author":"Sanno","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11102-005-1757-1","article-title":"Retrospective Multicentric Study of Pituitary Incidentalomas","volume":"7","author":"Day","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","article-title":"Nonfunctioning Pituitary Tumors and Pituitary Incidentalomas","volume":"37","author":"Molitch","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.arcmed.2023.102917_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0007","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1017\/cjn.2015.301","article-title":"Sellar Masses: An Epidemiological Study","volume":"43","author":"Al-Dahmani","year":"2016","journal-title":"Canadian Journal of Neurological Sciences\/Journal Canadien des Sciences Neurologiques"},{"key":"10.1016\/j.arcmed.2023.102917_bib0008","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Li\u00e8ge, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s42000-018-0070-0","article-title":"Medical therapy for non-functioning pituitary tumors\u2014a critical approach","volume":"18","author":"Tampourlou","year":"2019","journal-title":"Hormones"},{"key":"10.1016\/j.arcmed.2023.102917_bib0011","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0224","article-title":"Natural history and surgical outcome of incidentally-discovered clinically non-functioning pituitary macroadenomas","author":"Constantinescu","year":"2023","journal-title":"Endocr Connect"},{"key":"10.1016\/j.arcmed.2023.102917_bib0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0013","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ando.2015.04.004","article-title":"Management of nonfunctioning pituitary incidentaloma","volume":"76","author":"Galland","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0014","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/EJE-13-0515","article-title":"Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients\u2019 characteristics","volume":"169","author":"Losa","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0015","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1210\/jc.2003-030859","article-title":"Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ando.2015.04.003","article-title":"Post-surgical management of non-functioning pituitary adenoma","volume":"76","author":"Cortet-Rudelli","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0018","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000339823","article-title":"Natural History of Postoperative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis","volume":"96","author":"Chen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102917_bib0019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0020","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2016-4061","article-title":"Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study from Two Large UK Centers","volume":"102","author":"Tampourlou","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0021","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/EJE-07-0099","article-title":"Relevance of Ki-67 and prognostic factors for recurrence\/progression of gonadotropic adenomas after first surgery","volume":"157","author":"Dubois","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EJE-11-0566","article-title":"Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma?","volume":"165","author":"Reddy","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1227\/01.NEU.0000126885.71242.D7","article-title":"The Role of Radiation Therapy after Surgical Resection of Nonfunctional Pituitary Macroadenomas","volume":"55","author":"Park","year":"2004","journal-title":"Neurosurgery"},{"key":"10.1016\/j.arcmed.2023.102917_bib0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2265.2000.01153.x","article-title":"Non-functioning pituitary adenomas: indications for postoperative radiotherapy","volume":"53","author":"Woollons","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0025","first-page":"398","article-title":"Influence of radiotherapy on long-term relapse in clinically non-secreting pituitary adenomas. A retrospective study (1970-1988)","volume":"2","author":"Jaffrain-Rea","year":"1993","journal-title":"Eur J Med"},{"key":"10.1016\/j.arcmed.2023.102917_bib0026","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO Classification of Pituitary Tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0027","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0028","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1210\/jc.2005-2552","article-title":"Observation Alone after Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma","volume":"91","author":"Dekkers","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0029","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/cen.13402","article-title":"Predictors for secondary therapy after surgical resection of nonfunctioning pituitary adenomas","volume":"87","author":"Ratnasingam","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000503256","article-title":"Clinically Nonfunctioning Pituitary Incidentalomas: Characteristics and Natural History","volume":"110","author":"Tresoldi","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102917_bib0031","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/cen.14877","article-title":"Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study","volume":"98","author":"Ayalon-Dangur","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0032","doi-asserted-by":"crossref","first-page":"D11","DOI":"10.1530\/EJE-21-0344","article-title":"Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma","volume":"185","author":"Greenman","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0033","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.arcmed.2023.102917_bib0034","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10014-022-00441-6","article-title":"Aggressive nonfunctioning pituitary neuroendocrine tumors","volume":"39","author":"Portovedo","year":"2022","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0035","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0036","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11102-011-0316-1","article-title":"Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas","volume":"15","author":"Gabalec","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0037","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1530\/eje.0.1410396","article-title":"Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro","author":"Florio","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0038","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11102-018-0865-7","article-title":"Management of NFAs: medical treatment","volume":"21","author":"Even-Zohar","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0039","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2265.2005.02295.x","article-title":"Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth","volume":"63","author":"Greenman","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.arcmed.2023.102917_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/COC.0000000000000505","article-title":"Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma","volume":"42","author":"Batista","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0041","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocrine Related Cancer"},{"key":"10.1016\/j.arcmed.2023.102917_bib0042","first-page":"506","article-title":"Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience","volume":"66","author":"Vargas-Ortega","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0043","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11060-022-04149-7","article-title":"Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma","volume":"160","author":"Iglesias","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0044","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/jcpt.13460","article-title":"Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis","volume":"46","author":"Fachi","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.arcmed.2023.102917_bib0045","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3171\/2022.12.JNS222118","article-title":"Pituitary adenomas with multiple cell lineage combinations: clinicopathological features and short-term prognosis","volume":"139","author":"Tang","year":"2023","journal-title":"J Neurosurg"},{"key":"10.1016\/j.arcmed.2023.102917_bib0046","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1\u20135) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0047","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study","volume":"97","author":"Ram\u00edrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arcmed.2023.102917_bib0048","first-page":"179","article-title":"Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from \u201cclinically nonfunctioning\u201d pituitary adenoma cells incubated in vitro","volume":"58","author":"Pawlikowski","year":"2007","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0049","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.mce.2007.12.011","article-title":"Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas","volume":"286","author":"Padova","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","article-title":"Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case\u2013control study","volume":"15","author":"Fusco","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0051","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","article-title":"Somatostatin agonists for treatment of acromegaly","volume":"286","author":"Ben-Shlomo","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/756069","article-title":"Clinical Characteristics and Treatment Outcome of 485 Patients with Nonfunctioning Pituitary Macroadenomas","volume":"2015","author":"Vargas","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"Suppl. 1","key":"10.1016\/j.arcmed.2023.102917_bib0053","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102917_bib0054","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive Pituitary Tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.arcmed.2023.102917_bib0055","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0056","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used?","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.arcmed.2023.102917_bib0057","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0058","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.arcmed.2023.102917_bib0059","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1015366923810","article-title":"Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline","volume":"4","author":"Lohmann","year":"2001","journal-title":"Pituitary"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T09:14:52Z","timestamp":1741166092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0188440923001558"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102917","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Treatment of Non-Functioning Pituitary Adenomas","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102917"}}